This Topic Brief provides information on the impact of the COVID-19 pandemic on the behavioral health of the general public and healthcare workers, the impact of substance use disorders on COVID-19 outcomes, and other topics.
This Topic Brief aims to provide practical information and resources for using telehealth technologies to implement patient-centered integrated behavioral health care in primary and ambulatory care practices, including those related to substance use.
This guideline provide evidence-based strategies and standards of care for the treatment of stimulant use disorders, stimulant intoxication, and stimulant withdrawal, as well as secondary and tertiary prevention of harms associated with stimulant use.
This SAMHSA Advisory outlines the principles and components of low barrier care and how low barrier care may be leveraged to overcome substantial gaps in access, while also engaging individuals in treatment.
This public meeting explored real-world experiences and scientific evidence on emerging data trends for human xylazine exposure and examined concrete strategies for drug development and clinical research.
This virtual public meeting which explored real-world experiences and scientific evidence for buprenorphine initiation strategies, as well as medication dosing and management during continued treatment across different care settings
These guidelines provide practical clinical practice-based guidance, based on available research combined with emerging clinical experience, on the use of buprenorphine in the treatment of individuals using fentanyl and other highly potent synthetic opioids.
This free training includes nine modules on topics that include pregnancy care for patients with substance use disorder and the increasing rates of hepatitis C.